A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations
Abstract Objectives HER2 is an infrequently mutated driver gene in non‐small cell lung cancer (NSCLC). At present, there has been no comprehensive large‐scale clinical study to establish the optimal first‐line treatment strategy for advanced lung adenocarcinoma (LUAD) with HER2‐Mutant. Besides that,...
Guardat en:
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2024-06-01
|
| Col·lecció: | Cancer Medicine |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/cam4.7335 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|